Relevance of the Concept of Oncogene Addiction to Hormonal Carcinogenesis and Molecular Targeting in Cancer Prevention and Therapy

  • Bernard Weinstein
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 617)

The topic of this Symposium “Hormonal Carcinogenesis” is highly relevant to human cancer since in the USA and Western Europe, breast cancer (BC) is the most common cancer in women and prostate cancer (PC) is the most common cancer in men. Indeed, BC and PC account for about one-third of the total cancer incidence in women and men, respectively (1). Furthermore, although a few decades ago the incidence and mortality of BC and PC were relatively low in Asian countries, in recent years both of these cancers are becoming more frequent in Japan, Korea, Singapore, and urban China (2–4). The latter findings coupled with migration studies demonstrating an increase in BC and PC in Japanese living in Hawaii and the United States clearly indicate that exogenous factors play a major role in the causation of BC and PC. Therefore, in principle, it should be possible to prevent a major fraction of these cancers by identifying and modifying the various exogenous causative factors. Presumably, the recent increased incidence of BC and PC in Asian countries reflects “westernization”, but the specific factors have not been identified. This is an important and challenging task if we want to interrupt this literal epidemic of breast and prostate cancer in Asian countries.


Breast Cancer Androgen Receptor Prostate Specific Antigen LNCaP Cell African American 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Jemal A, Siegel R, Ward E, et al. (2007) Cancer statistics, 2007. CA Cancer J Clin 57: 43–66.PubMedCrossRefGoogle Scholar
  2. 2.
    Bray F, McCarron P, Parkin DM (2004) The changing global patterns of female breast cancer incidence and mortality. Breast Cancer Res 6: 229–239.PubMedCrossRefGoogle Scholar
  3. 3.
    Sim HG, Cheng CW (2005) Changing demography of prostate cancer in Asia. Eur J Cancer 41: 834–845.PubMedCrossRefGoogle Scholar
  4. 4.
    Park SK, Sakoda LC, Kang D, et al. (2006) Rising prostate cancer rates in South Korea. Prostate 66: 1285–1291.PubMedCrossRefGoogle Scholar
  5. 5.
    Willett, WR, B, Hankinson SE. Non-Genetic factors in the causation of breast cancer, Personal communication.Google Scholar
  6. 6.
    Giovannaccu E (2006) in Prostate Cancer: Principles and Practice (ed. Kirby R, P. A., Feneley M, Parsons JK eds.) (Taylor & Francis, 2006).Google Scholar
  7. 7.
    Dong B, Kim S, Hong S, et al. (2007) An infectious retrovirus susceptible to an IFN antiviral pathway from human prostate tumors. Proc Natl Acad Sci USA 104(5): 1655–1660.PubMedCrossRefGoogle Scholar
  8. 8.
    Weinstein IB (2002) Cancer. Addiction to oncogenes – the Achilles heal of cancer. Science 297: 63–64.PubMedCrossRefGoogle Scholar
  9. 9.
    Weinstein IB, Joe AK (2006) Mechanisms of disease: Oncogene addiction – a rationale for molecular targeting in cancer therapy. Nat Clin Pract Oncol 3: 448–457.PubMedCrossRefGoogle Scholar
  10. 10.
    Beatson G (1896) On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet ii: 104–107 and 162–165.Google Scholar
  11. 11.
    Lathrop AE, Loeb L (1916) Further investigations on the origin of tumors in mice. III. On the part played by internal secretion in the spontaneous development of tumors. J Cancer Res 1: 1–19.PubMedGoogle Scholar
  12. 12.
    Murray W (1928) Ovarian secretion and tumor incidence. Cancer Res 12: 18–25.Google Scholar
  13. 13.
    Huggins CB, SR, Jr, Hodges CV (1941) Studies in prostatic cancer. II. The effect of castration on advanced carcinoma of the prostate gland. Arch Surg 209–223.Google Scholar
  14. 14.
    Moody SE, Sarkisian CJ, Hahn KT, et al. (2002) Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis. Cancer Cell 2: 451–461.PubMedCrossRefGoogle Scholar
  15. 15.
    Moody SE, Perez D, Pan TC, et al. (2005) The transcriptional repressor Snail promotes mammary tumor recurrence. Cancer Cell 8: 197–209.PubMedCrossRefGoogle Scholar
  16. 16.
    D’Cruz CM, Gunther EJ, Boxer RB, et al. (2001) c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations. Nat Med 7: 235–239.PubMedCrossRefGoogle Scholar
  17. 17.
    Gunther EJ, Moody SE, Belka GK, et al. (2003) Impact of p53 loss on reversal and recurrence of conditional Wnt-induced tumorigenesis. Genes Dev 17: 488–501.PubMedCrossRefGoogle Scholar
  18. 18.
    Colomer R, Lupu R, Bacus SS, et al. (1994) erbB-2 antisense oligonucleotides inhibit the proliferation of breast carcinoma cells with erbB-2 oncogene amplification. Br J Cancer 70: 819–825.PubMedGoogle Scholar
  19. 19.
    Slamon DJ, Leyland-Jones B, Shak S, et al. (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783–792.PubMedCrossRefGoogle Scholar
  20. 20.
    Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353: 1659–1672.PubMedCrossRefGoogle Scholar
  21. 21.
    Pienta KJ, Bradley D (2006) Mechanisms underlying the development of androgen-independent prostate cancer. Clin Cancer Res 12: 1665–1671.PubMedCrossRefGoogle Scholar
  22. 22.
    Lim JT, Mansukhani M, Weinstein IB (2005) Cyclin-dependent kinase 6 associates with the androgen receptor and enhances its transcriptional activity in prostate cancer cells. Proc Natl Acad Sci USA 102: 5156–5161.PubMedCrossRefGoogle Scholar
  23. 23.
    Deguchi A, Thompson WJ, Weinstein IB (2004) Activation of protein kinase G is sufficient to induce apoptosis and inhibit cell migration in colon cancer cells. Cancer Res 64: 3966–3973.PubMedCrossRefGoogle Scholar
  24. 24.
    Lim JT, Piazza GA, Han EK, et al. (1999) Sulindac derivatives inhibit growth and induce apoptosis in human prostate cancer cell lines. Biochem Pharmacol 58: 1097–1107.PubMedCrossRefGoogle Scholar
  25. 25.
    Goluboff ET, Shabsigh A, Saidi JA, et al. (1999) Exisulind (sulindac sulfone) suppresses growth of human prostate cancer in a nude mouse xenograft model by increasing apoptosis. Urology 53: 440–445.PubMedCrossRefGoogle Scholar
  26. 26.
    Goluboff ET, Prager D, Rukstalis D, et al. (2001) Safety and efficacy of exisulind for treatment of recurrent prostate cancer after radical prostatectomy. J Urol 166: 882–886.PubMedCrossRefGoogle Scholar
  27. 27.
    Lim JT, Piazza GA, Pamukcu R, et al. (2003) Exisulind and related compounds inhibit expression and function of the androgen receptor in human prostate cancer cells. Clin Cancer Res 9: 4972–4982.PubMedGoogle Scholar
  28. 28.
    Han EK, Arber N, Yamamoto H, et al. (1998) Effects of sulindac and its metabolites on growth and apoptosis in human mammary epithelial and breast carcinoma cell lines. Breast Cancer Res Treat 48: 195–203.PubMedCrossRefGoogle Scholar
  29. 29.
    Lim JT, Joe AK, Suzui M, et al. (2006) Sulindac sulfide and exisulind inhibit expression of the estrogen and progesterone receptors in human breast cancer cells. Clin Cancer Res 12: 3478–3484.PubMedCrossRefGoogle Scholar
  30. 30.
    Shimizu M, Deguchi A, Lim JT, et al. (2005) (-)-Epigallocatechin gallate and polyphenon E inhibit growth and activation of the epidermal growth factor receptor and human epidermal growth factor receptor-2 signaling pathways in human colon cancer cells. Clin Cancer Res 11: 2735–2746.PubMedCrossRefGoogle Scholar
  31. 31.
    Sun CL, Yuan JM, Koh WP, et al. (2006) Green tea, black tea and breast cancer risk: a meta-analysis of epidemiological studies. Carcinogenesis 27: 1310–1315.PubMedCrossRefGoogle Scholar
  32. 32.
    Wu AH, Tseng CC, Van Den Berg D, et al. (2003) Tea intake, COMT genotype, and breast cancer in Asian–American women. Cancer Res 63: 7526–7529.PubMedGoogle Scholar
  33. 33.
    Kavanagh KT, Hafer LJ, Kim DW, et al. (2001) Green tea extracts decrease carcinogen-induced mammary tumor burden in rats and rate of breast cancer cell proliferation in culture. J Cell Biochem 82: 387–398.PubMedCrossRefGoogle Scholar
  34. 34.
    Masuda M, Suzui M, Lim JT, et al. (2003) Epigallocatechin-3-gallate inhibits activation of HER-2/neu and downstream signaling pathways in human head and neck and breast carcinoma cells. Clin Cancer Res 9: 3486–3491.PubMedGoogle Scholar
  35. 35.
    Pianetti S, Guo S, Kavanagh KT, et al. (2002) Green tea polyphenol epigallocatechin-3 gallate inhibits Her-2/neu signaling, proliferation, and transformed phenotype of breast cancer cells. Cancer Res 62: 652–655.PubMedGoogle Scholar
  36. 36.
    Jian L, Xie LP, Lee AH, et al. (2004) Protective effect of green tea against prostate cancer: a case-control study in southeast China. Int J Cancer 108: 130–135.PubMedCrossRefGoogle Scholar
  37. 37.
    Hiipakka RA, Zhang HZ, Dai W, et al. (2002) Structure-activity relationships for inhibition of human 5alpha-reductases by polyphenols. Biochem Pharmacol 63: 1165–1176.PubMedCrossRefGoogle Scholar
  38. 38.
    Adhami VM, Siddiqui IA, Ahmad N, et al. (2004) Oral consumption of reen tea polyphenols inhibits insulin-like growth factor-I-induced signaling in an autochthonous mouse model of prostate cancer. Cancer Res 64: 8715–8722.PubMedCrossRefGoogle Scholar
  39. 39.
    Caporali A, Davalli P, Astancolle S, et al. (2004) The chemopreventive action of catechins in the TRAMP mouse model of prostate carcinogenesis is accompanied by clusterin over-expression. Carcinogenesis 25: 2217–2224.PubMedCrossRefGoogle Scholar
  40. 40.
    Bettuzzi S, Brausi M, Rizzi F, et al. (2006) Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study. Cancer Res 66: 1234–1240.PubMedCrossRefGoogle Scholar
  41. 41.
    Shimizu M, Deguchi A, Joe AK, et al. (2005) EGCG inhibits activation of HER3 and expression of cyclooxygenase-2 in human colon cancer cells. J Exp Ther Oncol 5: 69–78.PubMedGoogle Scholar
  42. 42.
    Shimizu M, Deguchi A, Hara Y, et al. (2005) EGCG inhibits activation of the insulin-like growth factor-1 receptor in human colon cancer cells. Biochem Biophys Res Commun 334: 947–953.PubMedCrossRefGoogle Scholar
  43. 43.
    Renehan AG, Zwahlen M, Minder C, et al. (2004) Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 363: 1346–1353.PubMedCrossRefGoogle Scholar
  44. 44.
    Blakely CM, Stoddard AJ, Belka GK, et al. (2006) Hormone-induced protection against mammary tumorigenesis is conserved in multiple rat strains and identifies a core gene expression signature induced by pregnancy. Cancer Res 66: 6421–6431.PubMedCrossRefGoogle Scholar
  45. 45.
    Guarente L (2006) Sirtuins as potential targets for metabolic syndrome. Nature 444: 868–874.PubMedCrossRefGoogle Scholar
  46. 46.
    Hu Z, Fan C, Oh DS, et al. (2006) The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 7: 96.PubMedCrossRefGoogle Scholar
  47. 47.
    Carey LA, Perou CM, Livasy CA, et al. (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295: 2492–2502.PubMedCrossRefGoogle Scholar
  48. 48.
    Suganuma M, Okabe S, Kai Y, et al. (1999) Synergistic effects of (–)-epigallocatechin gallate with (–)-epicatechin, sulindac, or tamoxifen on cancer-preventive activity in the human lung cancer cell line PC-9. Cancer Res 59: 44–47.PubMedGoogle Scholar
  49. 49.
    Khafif A, Schantz SP, Chou TC, et al. (1998) Quantitation of chemopreventive synergism between (-)-epigallocatechin-3-gallate and curcumin in normal, premalignant and malignant human oral epithelial cells. Carcinogenesis 19: 419–424.PubMedCrossRefGoogle Scholar

Copyright information

© Springer 2008

Authors and Affiliations

  • Bernard Weinstein
    • 1
  1. 1.Columbia UniversityNew YorkUSA

Personalised recommendations